CD22 and neoplasm: In vivo, this anti-CD22-NMS249 ADC was at least as effective as an anti-CD22-VC-MMAE ADC in xenograft tumor models but retained its effectiveness in a model based on cell lines resistant to the anti-CD22-VC-MMAE ADC.